tetano
Editor, Senior Moderator
Nanotechnology
. 2023 Dec 15.
doi: 10.1088/1361-6528/ad1644. Online ahead of print. Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery
Xuemei Li[SUP] 1 [/SUP], Xueliang Xiu[SUP] 1 [/SUP], Rui Su[SUP] 1 [/SUP], Shichao Ma[SUP] 1 [/SUP], Zhipeng Li[SUP] 1 [/SUP], Li Zhang[SUP] 1 [/SUP], Zhi Wang[SUP] 1 [/SUP], Yihan Zhu[SUP] 1 [/SUP], Fengsen Ma[SUP] 1 [/SUP]
Affiliations
Mucosal delivery systems have gained much attention as effective way for antigen delivery that induces both systemic and mucosal immunity. However, mucosal vaccination faces the challenges of mucus barrier and effective antigen uptake and presentation. In particular, split, subunit and recombinant protein vaccines that do not have an intact pathogen structure lack the efficiency to stimulate mucosal immunity. In this study, poly (lactic acid-co-glycolic acid-polyethylene glycol) (PLGA-PEG) block copolymers were modified by mannose to form a PLGA-PEG-Man conjugate (mannose modified PLGA-PEG), which were characterized. The novel nanoparticles (NPs) prepared with this material had a particle size of about 150 nm and a zeta potential of -15 mV, and possessed ideal mucus permeability, immune cell targeting, stability and low toxicity. Finally, PLGA-PEG-Man nanoparticles (PLGA-PEG-Man NPs) were successfully applied for intranasal delivery of split influenza vaccine in rat for the first time, which triggered strong systemic and mucosal immune responses. These studies suggest that PLGA-PEG-Man NPs could function as competitive potential nano-adjuvants to address the challenge of inefficient mucosal delivery of non-allopathogenic antigens.
Keywords: adjuvant; mannose modification; nanoparticle; nasal mucosal delivery; split influenza vaccine.
. 2023 Dec 15.
doi: 10.1088/1361-6528/ad1644. Online ahead of print. Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery
Xuemei Li[SUP] 1 [/SUP], Xueliang Xiu[SUP] 1 [/SUP], Rui Su[SUP] 1 [/SUP], Shichao Ma[SUP] 1 [/SUP], Zhipeng Li[SUP] 1 [/SUP], Li Zhang[SUP] 1 [/SUP], Zhi Wang[SUP] 1 [/SUP], Yihan Zhu[SUP] 1 [/SUP], Fengsen Ma[SUP] 1 [/SUP]
Affiliations
- PMID: 38100843
- DOI: 10.1088/1361-6528/ad1644
Mucosal delivery systems have gained much attention as effective way for antigen delivery that induces both systemic and mucosal immunity. However, mucosal vaccination faces the challenges of mucus barrier and effective antigen uptake and presentation. In particular, split, subunit and recombinant protein vaccines that do not have an intact pathogen structure lack the efficiency to stimulate mucosal immunity. In this study, poly (lactic acid-co-glycolic acid-polyethylene glycol) (PLGA-PEG) block copolymers were modified by mannose to form a PLGA-PEG-Man conjugate (mannose modified PLGA-PEG), which were characterized. The novel nanoparticles (NPs) prepared with this material had a particle size of about 150 nm and a zeta potential of -15 mV, and possessed ideal mucus permeability, immune cell targeting, stability and low toxicity. Finally, PLGA-PEG-Man nanoparticles (PLGA-PEG-Man NPs) were successfully applied for intranasal delivery of split influenza vaccine in rat for the first time, which triggered strong systemic and mucosal immune responses. These studies suggest that PLGA-PEG-Man NPs could function as competitive potential nano-adjuvants to address the challenge of inefficient mucosal delivery of non-allopathogenic antigens.
Keywords: adjuvant; mannose modification; nanoparticle; nasal mucosal delivery; split influenza vaccine.